Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model DOI Creative Commons
Clive Pritchard,

Lucie Kutikova,

Richard Pitman

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 187 - 187

Published: Feb. 14, 2025

Background/Objectives: Vaccination against SARS-CoV-2 remains a key measure to control COVID-19. Nuvaxovid, recombinant Matrix-M-adjuvanted protein-based vaccine, showed similar efficacy mRNA vaccines in clinical trials and real-world studies, with lower rates of reactogenicity. Methods: To support decision making on UK vaccine selection, population-based compartmental dynamic transmission model cost-utility component was developed evaluate the cost-effectiveness Nuvaxovid compared from National Health Service perspective. The calibrated official epidemiology statistics for mortality, incidence, hospitalisation. Scenario sensitivity analyses were conducted. Results: In probabilistic base case, Nuvaxovid-only strategy provided total incremental cost savings GBP 1,338,323 1558 additional quality-adjusted life years (QALYs) an mRNA-only vaccination strategy. Cost driven by reduced cold chain-related operational costs wastage, while QALY gains potential differences tolerability. Probabilistic analysis indicated approximately 70% probability versus across most thresholds (up 300,000/QALY gained). Conclusions: remained dominant over scenario assessing waning, market shares, vaccinated population.

Language: Английский

Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs DOI

Darvin Scott Smith,

Maarten J. Postma, David N. Fisman

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 51, P. 126879 - 126879

Published: Feb. 15, 2025

Language: Английский

Citations

1
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model DOI Creative Commons
Clive Pritchard,

Lucie Kutikova,

Richard Pitman

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 187 - 187

Published: Feb. 14, 2025

Background/Objectives: Vaccination against SARS-CoV-2 remains a key measure to control COVID-19. Nuvaxovid, recombinant Matrix-M-adjuvanted protein-based vaccine, showed similar efficacy mRNA vaccines in clinical trials and real-world studies, with lower rates of reactogenicity. Methods: To support decision making on UK vaccine selection, population-based compartmental dynamic transmission model cost-utility component was developed evaluate the cost-effectiveness Nuvaxovid compared from National Health Service perspective. The calibrated official epidemiology statistics for mortality, incidence, hospitalisation. Scenario sensitivity analyses were conducted. Results: In probabilistic base case, Nuvaxovid-only strategy provided total incremental cost savings GBP 1,338,323 1558 additional quality-adjusted life years (QALYs) an mRNA-only vaccination strategy. Cost driven by reduced cold chain-related operational costs wastage, while QALY gains potential differences tolerability. Probabilistic analysis indicated approximately 70% probability versus across most thresholds (up 300,000/QALY gained). Conclusions: remained dominant over scenario assessing waning, market shares, vaccinated population.

Language: Английский

Citations

0